Impaired glycemia increases disease progression in mild cognitive impairment.
Impaired glycemia increases disease progression in mild cognitive impairment.
复制标题
DOI：
10.1016/j.neurobiolaging.2013.09.033
复制
发表时间：
2014-03
影响因子：
4.2
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Morris JK;Vidoni ED;Honea RA;Burns JM;Alzheimer's Disease Neuroimaging Initiative
胰岛素抵抗和2型糖尿病与认知能力下降和阿尔茨海默病(AD)风险增加有关。相对较少的研究评估了代谢功能障碍对轻度认知障碍(MCI)患者转换为AD的影响，目前尚不清楚MCI患者的血糖状态是否与认知功能下降和脑结构的临床相关指标有关。这项研究使用阿尔茨海默病神经成像计划(ADNI)数据库来检查基线血糖与转换为AD以及纵向临床、认知和成像指标下降的关系。有基线和2年临床痴呆评分(CDR)数据的MCI受试者(n=264)根据美国糖尿病协会(ADA)的基线空腹血糖标准进行分类。这些组为“正常血糖”组(Fg<；100 mg/dL；n=167)或“受损血糖”组(Fg≥100 mg/dL，n=97)。“血糖受损”组包括空腹血糖达到空腹血糖受损的ADA临界点的个体或诊断为糖尿病的个体。两年后评估CDR盒总和(CDR-SB)、认知能力测试(“整体认知”)、脑体积(全脑和海马体体积)、FDG-PET和AD转换率。与血糖受损的受试者相比，基线血糖正常的受试者在2年内的功能(CDR-SB)和整体认知能力下降较少。血糖正常的受试者失去的全脑体积也较少，从MCI到AD的转化率也较低。两组大鼠海马区体积变化及FDG-PET无明显差异。这些结果表明，基线血糖与认知功能下降和进展为AD有关。
Insulin resistance and Type 2 Diabetes are associated with cognitive decline and increased risk for Alzheimer’s disease (AD). Relatively few studies have assessed the impact of metabolic dysfunction on conversion to AD in mild cognitive impairment (MCI), and it is unclear whether glycemic status is associated with clinically-relevant measures of cognitive decline and brain structure in MCI. This study used the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database to examine the relationship of baseline glycemia with conversion to AD and longitudinal clinical, cognitive, and imaging measures of decline. MCI subjects (n=264) with baseline and 2-year clinical dementia rating (CDR) data available were classified according to American Diabetes Association (ADA) criteria for fasting glucose at baseline. These groups were “normoglycemic” (FG<100mg/dL; n= 167) or “impaired glycemia” (FG ≥100mg/dL, n=97). The “impaired glycemia” group included individuals with fasting glucose that either reached the ADA cut-point for impaired fasting glucose or individuals with diagnosed diabetes. Two-year change in CDR sum of boxes (CDR-SB), cognitive performance testing (“global cognition”), brain volume (whole brain and hippocampal volume), FDG-PET, and conversion to AD were assessed. Subjects with normoglycemia at baseline had less functional (CDR-SB) and global cognitive decline over 2 years than subjects with impaired glycemia. Normoglycemic subjects also lost less whole brain volume and exhibited lower conversion from MCI to AD. There was no difference in hippocampal volume change or FDG-PET between groups. These results suggest that baseline glycemia is related to cognitive decline and progression to AD.
登录
查看更多内容
影响因子：
158.5
作者：
Knowler, WC;Barrett-Connor, E;Nathan, DM
通讯作者：
Nathan, DM
影响因子：
3.8
作者：
Ragogna, Francesca;Lattuada, Guido;Perseghin, Gianluca
通讯作者：
Perseghin, Gianluca
影响因子：
7.7
作者：
Xu W;Caracciolo B;Wang HX;Winblad B;Bäckman L;Qiu C;Fratiglioni L
通讯作者：
Fratiglioni L
影响因子：
16.2
作者：
Cowie, Catherine C.;Engelgau, Michael M.;Gregg, Edward W.
通讯作者：
Gregg, Edward W.
影响因子：
16.2
作者：
Yamashita, S;Nakamura, T;Matsuzawa, Y
通讯作者：
Matsuzawa, Y